To evaluate the potential for pharmacokinetic (PK) drug-drug interactions (DDIs) between atogepant and topiramate, as well as to evaluate the safety and tolerability profiles when these 2 medications are coadministered vs administered alone.
Latest Information Update: 30 May 2022
At a glance
- Drugs Atogepant (Primary) ; Topiramate (Primary)
- Indications Migraine
- Focus Adverse reactions; Pharmacokinetics
- 30 May 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022